Treatment
Eculizumab clinical trials
We’re tracking 6 recruiting studies that include Eculizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07707687RecruitingPhase 2
Eculizumab for high-risk TA-TMA after stem cell transplant
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
Changsha, HunanAges 18 years+ - NCT05726916RecruitingPhase 3
Eculizumab for severe kidney and blood clotting emergencies in adults
This trial studies eculizumab, a targeted blood-clotting and immune system medicine, for adults hospitalized with hypertensive emergency–associated hemolytic uremic syndrome (a serious condition affecting kidneys and blood). It aims to see whether the drug can improve outcomes after this life-threatening event.
ParisAges 18 years+ - NCT06449001RecruitingPhase 3
Danicopan plus standard therapy for pediatric PNH
This trial tests adding danicopan to a standard treatment (ravulizumab or eculizumab) for children with PNH who still have anemia from extravascular hemolysis. The goal is to see if the combination helps improve red blood cell counts.
Saskatoon, SaskatchewanAges 12–17 - NCT06932744RecruitingPhase 3
Testing a new PNH pill for people who haven't had complement therapy
This study tests a new oral medication called MY008211A for people with PNH who have not yet tried complement inhibitors. It aims to improve anemia and reduce the need for blood transfusions by targeting the part of the immune system that destroys red blood cells.
Beijing, Beijing MunicipalityAges 18–75 - NCT07410039RecruitingPhase 4
Acute treatment for neuromyelitis optica in real-world setting
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
BeijingAges 18–65 - NCT07420296RecruitingPhase 3
Modified zipper therapy for AQP4-positive neuromyelitis optica
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
TianjinAges 18–80
What Eculizumab is being studied for
Conditions with recruiting Eculizumab studies.
Common questions
- Are there clinical trials studying Eculizumab?
- Yes. Clin2 currently lists 6 recruiting studies that include Eculizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Eculizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Eculizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Eculizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.